Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2774828 | 1.00 | GRIN2B (0.41) | GRIN2BGRIN2CUSP2SMN1; SMN2CTSK | |
| SCHEMBL1268184 | 1.00 | GRIN2B (0.41) | GRIN2BGRIN2CUSP2SMN1; SMN2CTSK | |
| SCHEMBL4002726 | 0.93 | GRIN2B (0.38) | GRIN2BGRIN2CUSP2SMN1; SMN2CTSK | |
| SCHEMBL2429525 | 0.90 | GRIN2B (0.41) | GRIN2BGRIN2CUSP2SMN1; SMN2CTSK | |
| SCHEMBL3370511 | 0.90 | GRIN2B (0.41) | GRIN2BGRIN2CUSP2SMN1; SMN2CTSK | |
| SCHEMBL4697633 | 0.87 | EPHX1 (0.46) | GRIN2BGRIN2CHPGDJAK3EPHX1 | |
| SCHEMBL2894589 | 0.87 | MAPK1 (0.40) | GRIN2BGRIN2CJAK3USP30GPR119 | |
| SCHEMBL4309286 | 0.84 | GRIN2B (0.40) | GRIN2BGRIN2CUSP2SMN1; SMN2CTSK | |
| SCHEMBL4437296 | 0.84 | GRIN2B (0.40) | GRIN2BGRIN2CUSP2SMN1; SMN2CTSK | |
| SCHEMBL692636 | 0.84 | GRIN2B (0.40) | GRIN2BGRIN2CUSP2SMN1; SMN2CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 607 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101695670-A | Catalysts for Baylis-Hillman reaction and preparation method thereof | NANJING UNIVERSITY OF TECHNOLOGY | 2010-04-21 | — | — | CN | claimed |
| US-12624122-B2 | Affinity maturated TAG72 specific single chain antibodies | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12612598-B2 | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4720089-A1 | COMPOSITIONS AND METHODS FOR IMAGING AND TREATING ENDOMETRIOSIS | Endomet Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720088-A1 | CONSTRAINED PEPTIDE INHIBITORS OF LRRK2-FADD INTERACTIONS | University of Georgia Research Foundation, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4713348-A1 | DOUBLY CONSTRAINED PEPTIDES AS ALLOSTERIC INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | University of Georgia Research Foundation, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12565520-B2 | Chemically-stabilized allosteric modulators of leucine-rich repeat kinase 2 (LRRK2) | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250297033-A1 | BISPECIFIC ANTIBODY FOR MEMBRANE CLEARANCE OF TARGET RECEPTORS | H LEE MOFFITT CANCER CT & RES (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250242062-A1 | ANTI-COX-2 NANOBODIES FOR ENDOSCOPIC VISUALIZATION OF COLORECTAL ADENOMAS | VANDERBILT UNIVERSITY | 2025-07-31 | — | — | US | disclosed |
| US-20250195688-A1 | Multiplexed Analysis of Materials for Tissue Delivery | GEORGIA TECH RESEARCH CORPORATION | 2025-06-19 | — | — | US | disclosed |
| US-5839443-A | Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1998-11-24 | — | — | US | disclosed |
| EP-0765341-A4 | TEMPLATE DIRECTED CYCLIZATION | SMITHKLINE BEECHAM CORP (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1998038861-A1 | ANTISENSE COMPOUNDS WHICH PREVENT CELL DEATH AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1998-09-11 | — | — | WO | disclosed |
| WO-1997042900-A9 | METHOD FOR INHIBITING THROMBOSIS IN A PATIENT WHOSE BLOOD IS SUBJECTED TO EXTRACORPOREAL CIRCULATION | — | 1998-03-05 | — | — | WO | disclosed |
| WO-1998001145-A1 | THERAPEUTIC APPLICATIONS OF T-BAM (CD40L) TECHNOLOGY TO TREAT DISEASES INVOLVING SMOOTH MUSCLE CELLS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1998-01-15 | — | — | WO | disclosed |
| WO-1997042900-A1 | METHOD FOR INHIBITING THROMBOSIS IN A PATIENT WHOSE BLOOD IS SUBJECTED TO EXTRACORPOREAL CIRCULATION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1997-11-20 | — | — | WO | disclosed |
| WO-1997035876-A1 | COMPOUNDS WHICH PREVENT NEURONAL CELL DEATH AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1997-10-02 | — | — | WO | disclosed |
| EP-0765341-A1 | TEMPLATE DIRECTED CYCLIZATION | SMITHKLINE BEECHAM CORPORATION (US) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995034577-A1 | TEMPLATE DIRECTED CYCLIZATION | SMITHKLINE BEECHAM CORPORATION (US) | 1995-12-21 | — | — | WO | disclosed |
| EP-0490667-A2 | HIV protease inhibitors | JAPAN ENERGY CORPORATION (JP) | 1992-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612598-B2 | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy | IL2, ICOS, IL2RA | GRIN2B 765/4885GRIN2C 3654/4885USP2 1872/4885 |
| US-12624122-B2 | Affinity maturated TAG72 specific single chain antibodies | IGLV6-57, CD74, IGSF11 | GRIN2B 3325/4885GRIN2C 3970/4885USP2 2478/4885 |
| US-12565520-B2 | Chemically-stabilized allosteric modulators of leucine-rich repeat kinase 2 (LRRK2) | LRRK2, SNCA, PARK7 | GRIN2B 412/4885GRIN2C 364/4885USP2 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.